Re: Chicharros USA - bolsa internacional
DRRX
DURECT is expecting an FDA advisory committee meeting on August 5, for the review of the New Drug Application (NDA) for chronic pain treatment Remoxy. Remoxy was resubmitted in March 2016 (it's going back to the FDA for a third time) by DURECT’s licensee Pain Therapeutics.FDA has accepted the resubmission and assigned a PDUFA date of September 25, 2016.According to Laidlaw analyst Jim Molloy, Remoxy represents $2.50, or more than half, of his $4/share valuation for the company.
http://www.investopedia.com/articles/insights/060216/important-catalysts-approaching-these-biotechs.asp#ixzz4Aa2Dth8A
----
Zacks analyst Grant Zeng reiterated a Buy rating on the stock, with a price target of $6, which implies an upside of 392% from current levels.
http://www.smarteranalyst.com/2016/05/11/analysts-reiterate-positive-stance-durect-corporation-drrx-ahead-fda-decision/